BACKGROUND: The aim of this study was to assess the safety and the efficacy of the novel @entity3446 -eluting Prolim   stent with a biodegradable polymer in the all-comers population. METHODS: We prospectively enrolled all @entity1 with stable @entity453 or @entity1187 treated with Prolim   stent between January and December 2013 in two interventional cardiology centers in Poland. Angiographic control was planned at 12  months, in which 15  % of @entity1 (randomly chosen) underwent optical coherence tomography imaging. The primary end-point was the cumulative rate of @entity204 , @entity583 , and @entity75 revascularization at 12  months. RESULTS: There were 204 @entity1 enrolled, in whom 238 Prolim   stents were deployed (1.17 stent per @entity1 ). The mean age was 68        10  years and 32.8  % were females. The examined stent was implanted in 5.9  % in STEMI @entity1 , in 21.6  % - in NSTE-ACS and in 72.5  % - in @entity1 with stable @entity453 . The Prolim   stent was most frequently implanted in right coronary artery (38.2  %) followed by left anterior descending artery (34.0  %). The cumulative major adverse cardiovascular events rate at 12  months was 6.9  %, and the clinically-driven @entity75 revascularization rate - 5.4  %. At 12  months in quantitative coronary angiography the late lumen loss was 0.21        0.18  mm, and in optical coherence tomography the mean neointima burden was 24.6        8.6  %. CONCLUSIONS: @entity3446 -eluting Prolim   stent with a biodegradable polymer is a feasible device with a very good safety profile and long-term clinical effectiveness. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT02545985 .

Novel XXXX -eluting stent Prolim   with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus', 'Sirolimus'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death']
@entity3446 :: (MESH:D020123,Chemical) :: ['sirolimus']
